



Advances in Angiogenesis, Inflammation, and Oxidative Stress in Inflammatory Bowel Diseases

Guest Editors:

Prof. Dr. Mihail Virgil Boldeanu

Department of Immunology-
Laboratory of Immunology,
Universitatea de Medicina si
Farmacie din Craiova, Craiova,
Romania

Prof. Dr. Dan Ionuț Gheonea

Department of Gastroenterology,
University of Medicine and
Pharmacy of Craiova, Craiova,
Romania

Deadline for manuscript
submissions:

closed (30 September 2025)

Message from the Guest Editors

Research over the last few decades has led to the use of biological therapy with human monoclonal antibodies, which has enabled the improved regulation of both the cellular immune response and inflammation of the intestinal mucosa, leading to clinical remission and endoscopic healing. However, there are patients in whom mucosal healing is not observed or alters the natural history of their inflammatory bowel disease.

In light of these observations, in this Special Issue, we will collect important studies (original research or review articles) regarding the evaluation of angiogenic, inflammatory, and oxidative stress in patients with IBD.

Studies investigating the hypothesis that angiogenesis and oxidative stress contribute significantly to mucosal inflammation in IBD are also welcome. Since symptoms are often subjective, and invasive procedures are often a burden for the patient, studying the interrelation between angiogenic factors, inflammatory markers, and oxidative stress factors will enable an objective measurement of disease activity.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)